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The conserved oligomeric Golgi (COG) complex is a tethering factor composed of eight subunits that is
involved in the retrograde transport of intra-Golgi components. Deficient biosynthesis of COG subunits
leads to alterations of protein trafficking along the secretory pathway and thereby to severe diseases in
humans. Since the COG complex affects the localization of several Golgi glycosyltransferase enzymes,
COG deficiency also leads to defective protein glycosylation, thereby explaining the classification of COG
deficiencies as forms of congenital disorders of glycosylation (CDG). To date, mutations in COG1, COG4,
COG7 and COG8 genes have been associated with diseases, which range from severe multi-organ disorders
to moderate forms of neurological impairment. In the present study, we describe a new type of COG
deficiency related to a splicing mutation in the COG5 gene. Sequence analysis in the patient identified a
homozygous intronic substitution (c.1669-15T>C) leading to exon skipping and severely reduced expression
of the COG5 protein. This defect was associated with a mild psychomotor retardation with delayed motor and
language development. Analysis of different serum glycoproteins revealed a CDG phenotype with typical
undersialylation of N- and O-glycans. Retrograde Golgi-to-endoplasmic reticulum trafficking was markedly
delayed in the patient’s fibroblast upon brefeldin-A treatment, which is a hallmark of COG deficiency. This
trafficking delay could be restored to normal values by expressing a wild-type COG5 cDNA in the patient
cells. This case demonstrates that COG deficiency and thereby CDG must be taken into consideration
even in children presenting mild neurological impairments.
INTRODUCTION
Glycosylation is a ubiquitous form of post-translational modifi-
cation that is essential in most living organisms. In humans,
defects of glycosylation cause diseases classified under the
generic name of congenital disorders of glycosylation (CDG).
The features of these diseases reflect the broad physiological
relevance of glycans, thereby ranging from multi-organ fail-
ures, dysmorphisms and skeletal malformations to hormonal
disorders and coagulopathies (1–3). The clinical manifestations
depend also on the type of glycosylation affected. Defects of
N-glycosylation are rather associated with neurological dis-
orders, whereas defects of O-mannosylation are linked to con-
genital muscular dystrophies (4) and defects of mucin-type
O-glycosylation for example with anemia (5) and tumoral
calcinosis (6).
Diagnosis of CDG is usually reached by isoelectric focusing
(IEF) of the serum proteins transferrin and apolipoprotein CIII
(ApoCIII) (7) followed by specific enzymatic assays and
mutation analysis (8,9). Most forms of CDG can be assigned
to mutations in genes participating in glycan biosynthesis
including glycosyltransferases, glycosidases, sugar transpor-
ters and enzymes involved in the production of substrates
for the glycosylation reactions. Only recently, defects in
genes involved in vesicular trafficking have been shown to
cause CDG. Mutations in the genes encoding subunits of the
conserved oligomeric Golgi (COG) complex were the first
group of CDG defects to be found outside of the glycosylation
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pathway (10–12). The COG complex has been described as a
cytosolic protein complex that is peripherally associated with
the Golgi serving as a tethering factor for retrograde vesicular
transport.
Todate,mutations ingenes encoding four of theCOGsubunits,
namelyCOG1, COG4, COG7 andCOG8, have been described as
causing CDG (13–17). In COG-deficient cells, the intra-Golgi
retrograde transport is disturbed, which affects the distribution
of so-called GEAR proteins (18). The GEAR protein family
includes SNARE proteins, the golgin and giantin matrix
proteins and glycosyltransferases and glycosidases, such as
a-mannosidase II, b1,2-N-acetylglucosaminyltransferase I,
a-2,3-sialyltransferase I (13,18,19). Because of the abnormal dis-
tribution of several glycosylation enzymes, COG deficiency is
usually associated with underglycosylation of proteins and thus
with typical CDG phenotypes. Besides leading to glycosylation
defects, COG deficient cells have previously been shown to
respond slowly to brefeldin-A (BFA) treatment (20). This drug
blocks the GDP/GTP-exchange factor of ADP-ribosylation
factor 1 and inhibits the formation of COPI vesicles on the
Golgi membrane. It leads to a rapid redistribution of Golgi pro-
teins into the endoplasmic reticulum (ER) (21), a process that
can be visualized by immunofluorescence microscopy of Golgi
resident proteins. Considering the combined impairment of ves-
icular trafficking and protein glycosylation, it is expected that
COG deficiency leads to severe diseases. However, as reported
here, it appears that COG deficiency can also be associated
with relatively mild clinical features.
RESULTS
The index patient is the first child of remotely consanguineous
parents of Iraqi origin. At her first neuropsychological exam-
ination at the age of 8 years, she showed global developmental
delay with moderate mental retardation (IQ around 50–55).
She showed no dysmorphic features, growth retardation or
ocular motor apraxia. However, her speech was slow and inar-
ticulate. She had a tendency to tumble and displayed truncal
ataxia and slight muscular hypotonia and showed a slight
coordination deficiency in the finger-nose test. Magnetic res-
onance imaging analysis showed pronounced diffuse atrophy
of the cerebellum and brain stem (data not shown). The supra-
tentorial brain parenchyma was without pathological findings.
Karyotype analysis, routine laboratory tests, such as measure-
ment of liver enzymes, alkaline phosphatase, lactate and
ammonia in blood as well as organic and amino acids in
urine were without pathological findings. Furthermore,
screens for inborn errors of metabolism including
thyrotropin-releasing-hormone, a-fetoprotein, very-long-chain
fatty acids and vitamin E were normal. At the age of 12, IEF of
serum transferrin was performed, leading to the first indication
for CDG (Fig. 1A). Now at 14 years, she has a good speech
perception, even tough her speed of speech is still slow. Her
language skills improved significantly and her education is
bilingual (Arabic/German). She remains mildly hypotonic,
with normal reflexes, good strength and truncal ataxia
without extrapyramidal signs. Blood for genomic DNA analy-
sis was drawn from all family members, whereas a skin biopsy
was taken only from the index patient.
The IEF of serum transferrin in the patient showed
increased levels of trisialo-transferrin that clearly differed
from the pattern of a control subject or a patient with a N-
glycosylation defect caused by a phosphomannomutase2
(PMM2) deficiency (Fig. 1A). This accumulation of trisialo-
transferrin is usually a sign of normal N-glycosylation site
occupancy but incomplete N-glycan structures. To investigate
the N-glycan structure, we have analyzed serum transferrin
using electrospray ionization mass spectrometry (Fig. 1B).
The observed transferrin peaks were assigned according to
the calculated molecular masses (22). In the patient sample,
an elevated peak at 79 248 Da was observed. The mass shift
of about 300 Da indicated the loss of a single sialic acid
residue in the glycoprotein. This finding was compatible
with the result obtained from the IEF analysis.
Considering the modest underglycosylation of serum trans-
ferrin, we assessed additional serum glycoproteins such as
haptoglobin and a1-acid glycoprotein (AGP). Haptoglobin
normally carries four N-glycans (23), whereas haptoglobin
from a PMM2-deficient patient shows underglycosylated
protein forms missing complete N-glycans (Fig. 1C).
However, haptoglobin from the present patient did not show
any loss of N-glycans, although it appeared to migrate slightly
faster in the SDS-PAGE compared with the control lane,
suggesting truncated glycan structures on the protein of the
patient (Fig. 1C). Enzymatic release of N-glycans with the
endoglycosidase PNGaseF led to identically deglycosylated
haptoglobin in all samples (Fig. 1C). The glycosylation
status of AGP was investigated by 2-D gel electorphoresis.
AGP contains five highly sialylated complex-type N-glycans
(24), and, due to its low pI narrow-range IEF it can be ana-
lyzed readily without purification steps (25). The molecular
masses of the AGP glycoforms were comparable in both
control and patient samples. However, a shift to more basic
pI values was observed in the patient sample (Fig. 1D). This
shift was compatible with reduced terminal sialylation of the
patient AGP. To determine whether reduced sialylation was
limited to N-glycans, we also analyzed the sialylation of the
serum O-glycoprotein ApoCIII. The IEF of control and
patient serum ApoCIII revealed the presence of unsialylated
ApoCIII in the patient sample (Fig. 1E).
A defect of terminal sialylation of both N- and O-glyans has
been previously described in patients with deficiency of the
COG complex (11,26). COG deficiency is associated with
delayed BFA-mediated collapse of the Golgi apparatus into
the ER (20), which represents a simple test to assess a possible
COG involvement in the underglycosylation of the present
patient. Treatment of control and patient fibroblasts with
BFA and monitoring of the Golgi structure by b1,4
galactosyltransferase-I immunofluorescence confirmed the
possibility of a COG deficiency, as shown by the
BFA-resistant phenotype in the patient cells (Fig. 2).
To detect possible mutations in COG genes, we first ampli-
fied the corresponding transcripts by RT–PCR. In this survey,
we noticed an unexpectedly short cDNA besides the normal
COG5 cDNA. Using various primer sets allowing the amplifi-
cation of partial stretches of the COG5 mRNA, we localized
the cause of the shorter transcript to a region of the COG5
gene encompassing exons 13–18 (Fig. 3A and B). Direct
sequencing of both COG5 cDNAs revealed the skipping of
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exons 15 and 16 in the shorter transcript. Sequence analysis
of the patient genomic DNA identified a homozygous
mutation in the intronic region 15 bp upstream of exon 15
(c.1669-15T.C), which is presumably leading to the observed
altered splicing. To exclude common single nucleotide
polymorphisms, we screened 200 unrelated alleles using a
MALDI-TOF-MS-based procedure for polymorphism geno-
typing (27). Fifty of these alleles were derived from samples
of similar ethnical and geographical region to the patient’s
family. None of the alleles analyzed carried the COG5
mutation c.1669-15T.C (data not shown). Haplotype analysis
of the family validated our findings since the parents both
carry the intronic mutation (Fig. 3C). The expression of the
shorter transcript was calculated to create a loss of 58 amino
acids (6.4 kDa) in the COG5 protein since the loss of exons
15 and 16 does not lead to a frameshift during translation.
To examine this finding, we analyzed the size and amount
of the COG5 protein by western blotting in control and
patient fibroblasts. As shown in Figure 3D, the low level of
full length COG5 protein detected in the patient fibroblasts
confirmed the disease-causing effect of the splicing mutation.
However, no shorter protein was observed, suggesting that the
truncated protein was unstable and prone to degradation.
To address whether the detected COG5 mutation was
uniquely responsible for the trafficking defect, we introduced
a wild-type COG5 cDNA by lentivirus-mediated transfection
in the patient fibroblasts. After confirming the stable
expression of the wild-type COG5 construct in the fibroblasts
Figure 1. Glycosylation of serum glycoproteins. (A) IEF of transferrin from healthy control (H), patient (P) and PMM2 deficient patient (PMM2). The number of
sialic acid residues is given on the left. (B) Electrospray ionization mass spectrometry analysis of transferrin from healthy control (H) and patient (P). The decon-
voluted mass spectra with the molecular masses (kDa) and the relative intensity are indicated. The fully glycosylated transferrin (tetrasialo) and the lighter
trisialo-transferrin are marked with arrows. (C) Western blot analysis of haptoglobin in healthy control (H), PMM2 deficient patient (PMM2) and patient
(P), before (2) and after (þ) PNGaseF treatment. (D) Narrow range 2-D gel electrophoresis of AGP from healthy control (H) and patient (P). Molecular
weight (MW) and isoelectric point (pI) are indicated. (E) IEF and immunoblotting of ApoCIII of healthy control (H) and patient (P). The number of sialic
acid residues is marked at the left.
Figure 2. Retrograde transport in BFA treated cells. Healthy control (H) and
patient (P) fibroblast were treated with BFA for the indicated time. The Golgi
apparatus was stained with b1,4 galactosyltransferase-I antibody. The scale
bar corresponds to 20 mm.
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(data not shown), we treated the cells with BFA and monitored
the collapse of the Golgi apparatus as done before. Whereas
the patient cells transfected with a mock lentivirus construct
showed the previously described delayed collapse of the
Golgi apparatus, the patient cells expressing the normal
COG5 cDNA showed the same rapid collapse of the Golgi
apparatus as normal cells, thereby confirming the causality
of the COG5 deficiency in the observed phenotype (Fig. 4).
As a control, we also showed that expression of either a
mock or a COG5 construct in normal fibroblasts did not sig-
nificantly affect the speed of the collapse.
DISCUSSION
The identification of forms of CDG caused by COG deficiency
marked a new era in CDG pathogenesis, since these defects
affect glycosylation indirectly through altered trafficking of
glycosyltransferases. To date, deficiencies in the COG1,
COG4, COG7 and COG8 subunits have been related to a
form of CDG. The first case identified, namely COG7
deficiency, was described for two siblings who died in their
first months of life (13). Subsequently identified COG7
patients were also severely affected so that it has been con-
cluded as COG7 deficiency is mainly a lethal multi-systemic
disorder (28,29). Two patients are known to be affected at
the COG8 locus (15,16). The clinical features were not as
severe as those observed in COG7 deficiency, but both
COG8 patients were strongly retarded. They showed obvious
neurological abnormalities and required hospitalization. Up
to now, the COG1 patients and the recently published COG4
case have represented the group with the mildest clinical fea-
tures (14,17,21,26,30). However, the present case of COG5
deficiency was even milder, since her clinical status allowed
her to live a regular life and to attend a college with thera-
peutic support.
The moderate clinical outcome of the present patient might
be explained by the rather mild glycosylation defect observed
in the COG5-deficient cells, since only terminal sialylation
was affected. This mild glycosylation phenotype yielded
only minor changes in the IEF profile of serum transferrin
(Fig. 1A), meaning that complementary tests, such as an
ESI-MS analysis, were required to confirm the pathological
nature of the finding. Considering the moderate clinical fea-
tures of the COG5-deficient patient and the nearly normal
transferrin IEF profile, we would recommend the application
of secondary tests in similar putative cases of CDG.
A similar weak glycosylation phenotype was also seen in
COG5-depleted HeLa cells (31) and a mild phenotype was
Figure 3. COG5 mutation analysis. (A) Schematic representation of the COG5
gene organization surrounding the mutation. The positions of the primers used
in the RT–PCR and of the mutation are indicated. (B) RT–PCR analysis of
mRNA isolated from healthy control (H) and patient (P) fibroblasts. The
primers used span exons 13–18. The healthy control cDNA fragment is
557 bp-long. The RT–PCR product from the patient sample showed an
additional, shorter fragment of 383 bp. The bp-marker is shown at the left.
(C) Electropherograms corresponding to the stretch of COG5 genomic DNA
encompassing the c.1669-15T.C mutation as detected from healthy control
DNA (H), patient DNA (P) and DNA from the parents of the patient. The
mutation is indicated by an arrow. (D) Steady-state levels of the COG5
protein detected by western blotting from healthy control (H) and patient
(P) fibroblasts. b-actin was used as loading control.
Figure 4. Retrograde transport in fibroblast cells expressing a wild-type COG5
cDNA. Healthy control (squares) and patient (triangles) fibroblasts were lenti-
virally transduced with either a mock (opened) or a COG5 cDNA (closed) con-
struct. The Golgi apparatus was stained with b1,4 galactosyltransferase-I
antibody. For each time point 250 cells were counted and the values expressed
in percents of cells with an ER-staining pattern.
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also noted in loss of COG5 function in Drosophila melanoga-
ster, which only affected spermatogenesis (32). In contrast,
analysis of patient cells with COG1 and COG7 defects
revealed that b1,4-linked galactose residues were also par-
tially missing in addition to decreased terminal sialylation
(17).
COG subunits may each mediate interaction with different
set of proteins, thus explaining varying severity of defects.
Defect at a single subunit does not obligatorily destabilize
the whole complex. Along this line, it has been shown that
deficiency of the TRAPPC2 subunit of the TRAPP complex,
another tethering factor, leads to a spondyloepiphyseal dyspla-
sia tarda, a disease affecting the secretion of some extracellu-
lar matrix proteins (33).
The intronic mutation in the COG5 allele is leading to
partial skipping of exons 15 and 16 and sequence analysis of
the shorter transcript suggested the expression of a truncated
COG5 protein in the patient cells, especially because the
shorter transcript was more abundant.
However, only the full length protein was detected upon
western blot analysis. We assume that the shorter COG5
protein is unstable and thus leading to its degradation.
The description of additional cases of COG deficiency will
eventually establish whether the severity of COG deficiency
relates to the affected COG subunit or rather to the level of
inactivation conferred by individual mutations irrespectively
of the subunits themselves.
Since the splicing mutation described here enabled the
expression of full-size COG5 protein, yet to low levels, we
would assume that other mutations may lead to more severe
forms of COG5 deficiency. The identification of a novel
mutation in the COG complex is important, since only
11 patients with defects in four of the subunits of the
complex have been described so far. It emphasizes that prob-
ably all the subunits are essential for correct Golgi trafficking
and glycosylation and it is likely that mutations in all subunits
of the COG complex could be identified soon among untyped
CDG cases. The present description of the COG5 defect in this
patient calls for a revision of the concept that COG
deficiencies represent rather severe forms of CDG. Accord-
ingly, we would recommend testing for possible COG
defects also among cases of mild neurological disorders.
MATERIALS AND METHODS
Glycosylation analysis of serum glycoproteins
IEF of transferrin was performed as described (7) using Immo-
biline DryPlates (pH 4–7, GE Healthcare) and the Phast
System (GE Healthcare). Two-dimensional SDS-PAGE for
AGP analysis was carried out as described by Kleinert et al.
(25). Transferrin was isolated from serum samples and ana-
lyzed with electrospray ionization mass spectrometry as
reported (22).
Antibodies and western blotting
Anti-haptoglobin was purchased from Rockland (Gilbertsville,
PA, USA) and anti-ApoCIII from ANAWA (Wangen, CH).
Anti-COG5 was a gift from Dr D. Ungar (University of
York, York, UK) and was used at a dilution of 1:100. Proteins
were separated by SDS-PAGE and immunoblotted. Signals
were detected using the ECL detection kit (Amersham Bio-
sciences). Enzymatic deglycosylation of serum haptoglobin
was performed using PNGase F (New England Biolabs).
Sequencing and mutation analysis of COG5 gene
Total RNA was isolated from fibroblasts using Qiagen RNeasy
Kit (Qiagen Inc.). Reverse transcription was performed using
QIAGEN OneStep RT–PCR Kit. Mutation screening of the
COG genes COG1 to COG8 was carried out by fluorescent
sequencing of cDNA-amplified PCR products on an ABI
3100 automated sequence detection system (Applied Biosys-
tems). PCR conditions and primer sequences are available
from the authors upon request. Genomic DNA was isolated
from peripheral blood leukocytes using DNeasy Blood &
Tissue Kit (Qiagen Inc.). For amplification of the COG5
cDNA region that was used to examine the skipping of
exons 15 and 16, respectively, the following primers were
used: 50-GATTATGATCCAGAAAAGGCT-30 (forward) and
50-GGATAATGACCCAGAAAAGTC-30 (reverse). These
primers span the exons 13–18. For amplification of the
genomic region that includes the mutation identified in this
study, the following primers were used: 50-TAACATTCTC
TTTGTCAGA-30 (forward) and 50-GCCAGAGTCAAAGAC
TGT-30 (reverse). The exact PCR protocols are available on
request.
Single nucleotide polymorphism analysis
The genomic DNA region containing the mutation was ampli-
fied using the forward and reverse primer pair 50-TAACATTC
TCTTTGTCAGA-30 (forward) and 50-GCCAGAGTCAAAG
ACTGT-30 (reverse). The PCR product was purified using
the QIAquick PCR purification kit (Qiagen Inc.) and used as
template for the allele-specific primer extension. The exten-
sion reaction was performed with the extension primer
50-TCATTCTGACACATTCTLTTTGAA-30 containing a
photocleavable linker. The exact PCR protocols are available
on request. The extended product was purified using the gen-
opure oligo kit (Bruker Daltonics) according to the manufac-
turer’s instructions. The sample was transferred to an
AnchorChip sample target (400 mm, Bruker Daltonics) pre-
loaded with 3-HPA matrix. After UV-cleavage of the linker,
molecular masses of the extension products were determined
with an Autoflex MALDI-TOF mass spectrometer (Bruker
Daltonics) in the linear mode.
Cell culture
A punch biopsy of skin from the upper arm was taken from the
index patient, minced and incubated in DMEM medium with
10% fetal calf serum, 0.5% penicillin and streptomycin (Invi-
trogen) at 378C under 5% CO2. Primary fibroblasts cultures
were obtained by expansion of fibroblast cells growing out
of skin explants after 7–14 days. The fibroblasts were
further cultured in DMEM with 10% fetal calf serum and
0.5% penicillin and streptomycin at 378C.
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BFA assay and immunofluorescence microscopy
Fibroblasts were grown over night on glass cover slips to
60% confluence. Medium was then changed with pre-
warmed medium containing 2 mg/ml of BFA (LC labora-
tories). The assay was stopped at different time points by
fixing the cells with 3% paraformaldehyde. The cells were per-
meabilized with 0.1% saponin in PBS followed by immunos-
taining using a mouse monoclonal antibody to the human b1,4
galactosyltransferase-I protein in a 1:50 dilution (gift from Dr
E.G. Berger, University of Zurich, Switzerland). Anti-mouse
Alexa Fluor-488 antibody was purchased from Molecular
Probes (Invitrogen) and pictures were taken with a fluor-
escence microscope (Axiovert 200, Zeiss).
Cloning of COG5 and transfection of fibroblasts
The vector encoding COG5 cDNA was obtained from Open
Biosystems (MHS1010-97227871). The terminal 113 bp of
COG5 missing in this construct were introduced as a
BamHI–XbaI PCR fragment amplified from fibroblast cDNA
with the following primer: 50-TTGGATCCTCCAGCTCAGG
AAAACCTGATG-30 (forward, including a BamHI restriction
site) and 50-CGTCTAGAGGGTTAGCACAAAGTGGAGAT
G-30 (reverse, including a XbaI restriction site). The complete
COG5 cDNA was then subcloned into pLenti6 vector (Invitro-
gen) using BamHI and SacII restriction sites. Transfection of
fibroblasts using lentiviral vectors was carried out as described
previously (34).
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